FDA 483 - EmCyte Corporation - November 15, 2023

EmCyte Corporation in Fort Myers, FL, a manufacturer, received two observations during an FDA inspection. The firm was cited for inadequate documentation of corrective and preventive action activities, specifically regarding the verification of effectiveness without established acceptance criteria. Additionally, their complaint handling procedures lacked established time frames for processing complaints.